BPC-157 wound and soft-tissue healing Preclinical reviews describe BPC-157 promoting healing across skin, muscle, tendon, ligament and the gut, tied to its angiogenic action [1]
If nausea onset coincides with 5-amino-1MQ introduction but tirzepatide dose was stable for 4+ weeks prior, the new compound is the likely culprit
Preclinical studies using T4 (including the RGN-259 ophthalmic clinical trials) have not identified significant adverse events at therapeutic doses
Negative recommendation: PCAC advises against inclusion, though this would not necessarily be the final word the FDA can still act independently
I have had a set back and just ordered what is hopefully my last round of hcg WITH lipo
Research shows BPC-157 treatment accelerates healing of transected tendons through promotion of tendon outgrowth, cell survival, and cell migration via regulation of ERK1/2 phosphorylation and downstream targets including c-Fos, c-Jun, and Egr-1key molecules involved in cell growth, migration, and angiogenesis